Clyde Biosciences

Clyde Biosciences is a contract research organisation specialising in preclinical cardiovascular safety assessment using human iPSC-derived cardiomyocytes.

Its proprietary platform measures membrane voltage, calcium transients and contractility in a single assay, providing high-resolution functional data on drug-induced cardiac effects.

The company has been a core participant in the FDA-led CiPA initiative validating in vitro cardiomyocyte assays for pro-arrhythmic risk prediction.

Clyde Biosciences serves pharmaceutical and biotechnology clients worldwide from facilities in Glasgow and Maryland, USA.